Print Page | Close Page

 
 

Curia Global

Address: 26 Corporate Circle Drive, Albany, New York. 12203
 
Country: USA
 
Parent: The Carlyle Group
 
Sectors: Contract Research & Development, Contract Manufacturing, Collaborations & Partnerships- R&D, Collaborations & Partnerships-Manufacture
 
Telephone: +1 (518) 512 2000
 
Fax: +1 (518) 512 2020
 
Website: https://curiaglobal.com/
 
- - -
 

Social Media

Facebook : https://www.facebook.com/AlbanyMolecularResearchInc
 
Google+ : https://plus.google.com/+Amriglobal
 
LinkedIn : https://www.linkedin.com/company/amri
 
Twitter : https://twitter.com/amriglobal?
 
YouTube : https://www.youtube.com/channel/UC7F8yGp21M7LuBqf5tE6wRg
 
- - -
 

About Us

Formerly AMRI, Curia is global contract research, development and manufacturing organization dedicated to helping our partners advance from curiosity to cure. With locations in North America, Europe and Asia, Curia’s team combines scientific expertise and market-leading technology to provide a complete suite of solutions in Discovery, Development, Analytical Services, API Manufacturing and Drug Product

We care about the quality and success of your projects as if they were our own. No matter the size of your project or the complexity of the challenge, our experts pinpoint and execute the precise solution to hit your target. From molecule to molecule, batch to batch, your product will benefit from our ingenuity.

 

 
- - -
 

Sectors

  • Contract Research & Development
  • Contract Manufacturing
 
  • Collaborations & Partnerships- R&D
  • Collaborations & Partnerships-Manufacture
 
- - -
 

Categories

  • Active Pharmaceutical Ingredients
  • Active Pharmaceutical Ingredients-Generics
  • Small Molecules
  • Large Molecules
  • Biologics
  • Drug Development Services
  • Drug Discovery Services
  • Nanoparticles
  • Liposomes
  • Lipids
  • Lipid Nanoparticles (LNPs)
  • Gene Editing
  • Messenger RNA
  • Viral Vectors
  • Gene Vectors
  • Cell Line Development
  • Proteins-Recombinant
  • Antibodies-monoclonals
  • Process Development
 
  • Biocatalysis
  • Finished Dosage
  • Bioprocess Development
  • Small Molecule Synthesis
  • High Potency API's
  • High Potency Formulations
  • Aseptic Processing
  • Clinical Trial Manufacturing
  • Vials-Filling Services
  • Syringes
  • Syringe Filling
  • Lyophilisation
  • Fermentation
  • Vaccine Manufacturing
  • Vaccine Products
  • Sterile Formulations
  • Fill & Finish
  • Controlled Status Products
 
- - -
 

Certifications

  • GMP- as per ICH Q7a
 
  • SafeBridge-Handling highly potent pharmaceutical compounds
 
- - -
 

News

 
27th March 2023
 

Curia Collaborates with Corning to Advance Biopharmaceutical Continuous-Flow Development and Manufacturing Programs

 

Albany, NY – March 23, 2023 – Curia, a leading contract research, development and manufacturing organization, today announced a collaboration with Corning Incorporated to expand and accelerate continuous-flow development and manufacturing programs for the chemical and biopharmaceutical industries globally. The collaboration with Corning’s Advanced-Flow™ Reactor (AFR) team includes the first installation of Corning’s G1 production system, designed for the continuous industrial production of active pharmaceutical ingredients (API).


 

 
-
 
 
12th July 2021
 

AMRI becomes Curia

 

Formerly AMRI, Curia is global contract research, development and manufacturing organization dedicated to helping our partners advance from curiosity to cure. With locations in North America, Europe and Asia, Curia’s team combines scientific expertise and market-leading technology to provide a complete suite of solutions in Discovery, Development, Analytical Services, API Manufacturing and Drug Product

 
-
 
 
07th September 2020
 

AMRI Selected to Support AstraZeneca in Delivery of COVID-19 Vaccine

 

ALBANY a leading global provider of advanced drug development and manufacturing solutions, today announced that it has signed a supply agreement with AstraZeneca to support the manufacture of AstraZeneca’s COVID-19 vaccine candidate AZD1222, intended to protect against the SARS-CoV-2 novel coronavirus.


“AMRI is proud to partner with AstraZeneca in pursuit of a vaccine that could protect people against the coronavirus pandemic”


On May 21, 2020, AstraZeneca announced it had received more than $1B from the U.S. Biomedical Advanced Research and Development Authority (BARDA) for the development, production and delivery of the COVID-19 vaccine it is developing in cooperation with University of Oxford.


AMRI has been chosen to contribute to the supply of the vaccine candidate through sterile fill/finish of AZD1222 at AMRI’s drug product manufacturing facility in Albuquerque, New Mexico. The COVID-19 vaccine program will take advantage of the facility’s cGMP manufacturing capacity to potentially produce millions of doses of AZD1222 annually. Preparations for this program have begun at the Albuquerque facility, and both organizations are committed to delivering on unprecedented manufacturing timelines.


“AMRI is proud to partner with AstraZeneca in pursuit of a vaccine that could protect people against the coronavirus pandemic,” said John Ratliff, CEO, AMRI. “Our experience in drug product fill/finish will enable timely manufacturing to make the vaccine available as soon as possible to advance bringing life-changing medicines to market.”

 
-
 
 
20th December 2017
 

AMRI expands sterile API capacity in Europe

 
CDMO Albany Molecular Research Inc., which was recently acquired by private investors, has bulked up its aseptic API capacity as it continues to expand globally.

The Albany, New York, contractor says it has more than doubled its current bulk API aseptic manufacturing capacity with the addition of a new line at its facility in Valladolid, Spain. The expansion will also work in conjunction with its aseptic API manufacturing at plants in Bon-Encontre and Tonneins, France. The company said it also completed an aseptic prefilled syringe line at its facility in Albuquerque, New Mexico.
 
-
 
 
15th July 2016
 

AMRI COMPLETES ACQUISITION OF EUTICALS

 
ALBANY, N.Y., July 11, 2016 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today announced that it has completed the acquisition of Prime European Therapeuticals S.p.A., also known as "Euticals", a privately-held company headquartered in Lodi, Italy, specializing in custom synthesis and the manufacture of active pharmaceutical ingredients (APIs). This completes the transaction initially announced on May 5, 2016.
 
-
 
 
01st July 2016
 

AMRI SELECTED AS A DEDICATED CHEMICAL BIOLOGY CONSORTIUM CENTER TO EXPAND DRUG DEVELOPMENT

 
The Frederick National Lab, sponsored by the National Cancer Institute, is managing the expansion of the Chemical Biology Consortium to 22 sites around the country with world-class expertise in high-throughput screening, structural biology, medicinal chemistry, compound profiling, cancer cell biology, and animal models for oncology. AMRI is participating in the consortium via a research subcontract from Leidos Biomedical Research, Inc., prime contractor for the national lab.
 
-
 
 
09th May 2016
 

AMRI acquires API business, expands into Europe

 
AMRI has acquired the Italy-based chemical company, Euticals, in a move that expands its API development and manufacturing business.
 
-
 
 
19th February 2016
 

M&A strategy paying off for AMRI; more API acquisitions to come

 
Controlled substances and peptides are on AMRI’s wish list as it profits from a growth strategy which has seen six acquisitions over the past two years.
 
- - -
 
Printed: 16-Apr-2026 at 11:54:07 hrs
Source: The Partnership Tree | https://www.pharmaservicesdirectory.com